About
Dr. Scott Rothbart is a Professor in the Department of Epigenetics at Van Andel Institute (VAI), where he leads the Rothbart Laboratory. He earned his B.S. in Food Science and Human Nutrition from the University of Florida and his Ph.D. in Pharmacology and Toxicology from Virginia Commonwealth University. His postdoctoral training was conducted under Dr. Brian Strahl at the University of North Carolina at Chapel Hill. His research focuses on understanding chromatin accessibility, histone post-translational modifications, and DNA methylation's role in disease, particularly cancer. He translates this basic research into epigenetic target identification and drug discovery.
Dr. Rothbart has contributed to groundbreaking studies on UHRF1’s role in DNA methylation maintenance and its therapeutic potential in cancer. He co-leads the VAI-SU2C Epigenetics Dream Team and directs the VAI Cancer Epigenetics Training Program. His work has been recognized with awards like the NIH MIRA Award and the American Cancer Society Research Scholar Grant.
Research Interests: Chromatin biochemistry, cancer epigenetics, functional proteomics, histone modifications, and epigenetic drug development. His lab develops tools like peptide microarrays and functional proteomics platforms to study histone modifiers and their clinical relevance.
Notable Achievements: Published over 122 peer-reviewed papers in 2024, including 63 in high-impact journals. Launched 15 clinical trials through the Epigenetics Dream Team. His lab’s work on viral mimicry therapies and epigenetic drug combinations has advanced cancer treatment strategies.
Education: B.S. University of Florida (2004), Ph.D. Virginia Commonwealth University (2009), Postdoctoral Fellowship UNC Chapel Hill (2014).
